Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice

Antiviral Research

Volumn 38, Issue 2, 1998, Pages 117-130

  Kostense, Stefan ^a   Sun, Wenn H ^b   Cottey, Robert ^a   Taylor, Scott F ^a   Harmeling, Stefan ^a   Zander, Dani ^a   Small Jr , Parker A ^a   Bender, Bradley S ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokine production; Influenza A virus infection; Interleukin 12; T helper type 1

Indexed keywords

BOVINE SERUM ALBUMIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 12; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; HELPER CELL; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS A; INTERFERON PRODUCTION; INTRAPERITONEAL DRUG ADMINISTRATION; MEDIASTINUM LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS TITRATION;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; FEMALE; IMMUNOGLOBULIN G; INFLAMMATION; INFLUENZA A VIRUS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKINS; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 0031870051     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00019-9     Document Type: Article

References (63)

1. Abraham E., Wunderink R., Silverman H., Perl T.M., Nasraway S., Levy H., Bone R., Wenzel R.P., Balk R., Allred R., Pennington J.E., Wherry J.C. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. J. Am. Med. Assoc. 273(12):1995;934-941.
2. Baumgarth N., Kelso A. In vivo blockade of IFNγ affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J. Virol. 70(7):1996;4411-4418.
3. Bender B.S., Small P.A. Jr. Heterotypic immune mice lose protection against influenza virus infection with senescence. J. Infect. Dis. 168(4):1993;873-880.
4. Bender B.S., Johnson M.P., Small P.A. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology. 72(4):1991;514-519.
5. Bender B.S., Bell W.E., Taylor S., Small P.A. Jr. Class I major histocompatibility complex-restricted cytotoxic T-lymphocytes are not necessary for heterotypic immunity to influenza. J. Infect. Dis. 170(5):1994;1195-1200.
6. Bender B.S., Croghan T., Zhang L., Small P.A. Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T-cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 175(4):1992;1143-1145.
7. Bender B.S., Taylor S.F., Zander D.S., Cottey R. Pulmonary immune response of young and aged mice after influenza challenge. J. Lab. Clin. Med. 126(2):1995;169-177.
8. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70(9):1996;6418-6424.
9. Betts R.F. Influenza virus. Mandell G.L., Bennett J.E., Dolin R. Principles and Practice of Infectious Diseases. 4th:1995;1546-1567 Churchill Livingstone, New York.
10. Bi Z., Quandt P., Komatsu T., Barna M., Reiss C.S. IL-12 promotes enhanced recovery from vesicular stomatitis virus infection of the central nervous system. J. Immunol. 155(12):1995;5684-5689.
11. Carding S.R., Allan W., McMickle A., Doherty P.C. Activation of cytokine genes in T-cells during primary and secondary murine influenza pneumonia. J. Exp. Med. 177(2):1993;475-482.
12. Carr J.A., Rogerson J., Mulqueen M.J., Roberts N.A., Booth R.F.G. IL-12 exhibits potent antiviral activity in experimental herpesvirus infections. J. Virol. 71(10):1997;7799-7803.
13. Chehimi J., Valiante N.M., D'Andrea A., Rengaraju M., Rosado Z., Kobayashi M., Perussia B., Wolf S.F., Starr S.E., Trinchieri G. Enhancing effect of natural killer cell stimulatory factor (NKSF/IL-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur. J. Immunol. 23(8):1993;1826-1830.
14. Conn C.A., McClellan J.L., Maassab H.F., Smitka C.W., Majde J.A., Kluger M.J. Cytokines and the acute phase response to influenza virus in mice. Am. J. Physiol. 268(1/2):1995;78-84.
15. D'Andrea A., Rengaraju M., Valiante N.M., Chehimi J., Kubin M., Aste M., Chan S.H., Kobayashi M., Young D., Nickbarg E. et al. Production of natural killer cell stimulatory factor (IL-12) by peripheral blood mononuclear cells. J. Exp. Med. 176(5):1992;1387-1398.
16. Eichelberger M., Allan W., Zijlstra M., Jaenisch R., Doherty P.C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T-cells. J. Exp. Med. 174(4):1991;875-880.
17. Flynn J.L., Goldstein M.M., Triebold K.J., Sypek J., Wolf S., Bloom B.R. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155(5):1995;2515-2524.
18. Fong Y., Moldawer L.L., Marano M., Wei H., Barber A., Manogue K., Tracey K.J., Kuo G., Fischman D.A., Cerami A. et al. Cachectin/TNF or IL-1α induces cachexia with redistribution of body proteins. Am. J. Physiol. 256(3/2):1989;659-665.
19. Fries L.F., Dillon S.B., Hildreth J.E., Karron R.A., Funkhouser A.W., Friedman C.J., Jones C.S., Culleton V.G., Clements M.L. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. J. Infect. Dis. 167(3):1993;593-601.
20. Gately, M.K., Mulqueen, M.J., 1996. IL-12: potential clinical applications in the treatment and prevention of infectious diseases. Drugs 52 (2), 18-25; discussion 25-56.
21. Gazzinelli R.T., Giese N.A., Morse H.C.R. In vivo treatment with IL-12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS). J. Exp. Med. 180(6):1994;2199-2208.
22. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., Kolsch E., Podlaski F.J., Gately M.K., Rude E. IL-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur. J. Immunol. 25(3):1995;823-829.
23. Gladue R.P., Laquerre A.M., Magna H.A., Carroll L.A., O'Donnell M., Changelian P.S., Franke A.E. In vivo augmentation of IFNγ with a rIL-12 human/mouse chimera: pleiotropic effects against infectious agents in mice and rats. Cytokine. 6(3):1994;318-328.
24. Gracie J.A., Bradley J.A. IL-12 induces IFNγ-dependent switching of IgG alloantibody subclass. Eur. J. Immunol. 26(6):1996;1217-1221.
25. Graham M.B., Braciale V.L., Braciale T.J. Influenza virus-specific CD4+ T helper type 2 T-lymphocytes do not promote recovery from experimental virus infection. J. Exp. Med. 180(4):1994;1273-1282.
26. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of IFNγ or IL-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T-cell subsets. J. Exp. Med. 169(1):1989;59-72.
27. Heinzel F.P., Schoenhaut D.S., Rerko R.M., Rosser L.E., Gately M.K. Recombinant IL-12 cures mice infected with Leishmania major. J. Exp. Med. 177(5):1993;1505-1509.
28. Hendrzak J.A., Brunda M.J. IL-12. Biologic activity, therapeutic utility and role in disease. Lab. Invest. 72(6):1995;619-637.
29. Hennet T., Ziltener H.J., Frei K., Peterhans E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J. Immunol. 149(3):1992;932-939.
30. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., Murphy K.M. Development of TH1 CD4+ T-cells through IL-12 produced by Listeria-induced macrophages. Science. 260(5107):1993;547-549.
31. Keane-Myers A., Maliszewski C.R., Finkelman F.D., Nickell S.P. Recombinant IL-4 treatment augments resistance to Borrelia burgdorferi infections in both normal susceptible and antibody-deficient susceptible mice. J. Immunol. 156(7):1996;2488-2494.
32. Kuwano K., Scott M., Young J.F., Ennis F.A. Active immunization against virus infections due to antigenic drift by induction of crossreactive cytotoxic T-lymphocytes. J. Exp. Med. 169(4):1989;1361-1371.
33. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor IL-12 induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177(4):1993;1199-1204.
34. Marinaro M., Boyaka P.N., Finkelman F.D., Kiyono H., Jackson R.J., Jirillo E., McGhee J.R. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185(3):1997;415-427.
35. Meitin C.A., Bender B.S., Small P.A. Jr. Enteric immunization of mice against influenza with recombinant vaccinia. Proc. Natl. Acad. Sci. USA. 91(23):1994;11187-11191.
36. Moran T.M., Isobe H., Fernandez-Sesma A., Schulman J.L. IL-4 causes delayed virus clearance in influenza virus-infected mice. J. Virol. 70(8):1996;5230-5235.
37. Morris S.C., Madden K.B., Adamovicz J.J., Gause W.C., Hubbard B.R., Gately M.K., Finkelman F.D. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol. 152(3):1994;1047-1056.
38. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136(7):1986;2348-2357.
39. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173.
40. Orange J.S., Salazar Mather T.P., Opal S.M., Spencer R.L., Miller A.H., McEwen B.S., Biron C.A. Mechanism of IL-2-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181(3):1995;901-914.
41. Orange J.S., Wolf S.F., Biron C.A. Effects of IL-12 on the response and susceptibility to experimental viral infections. J Immunol. 152(3):1994;1253-1264.
42. Ozmen L., Aguet M., Trinchieri G., Garotta G. The in vivo antiviral activity of IL-12 is mediated by IFNγ J. Virol. 69(12):1995;8147-8150.
43. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J. Virol. 69(4):1995;2075-2081.
44. Sadick M.D., Heinzel F.P., Holaday B.J., Pu R.T., Dawkins R.S., Locksley R.M. Cure of murine leishmaniasis with anti-IL-4 monoclonal antibody. Evidence for a T-cell-dependent, IFNγ-independent mechanism. J. Exp. Med. 171(1):1990;115-127.
45. Sarawar S.R., Carding S.R., Allan W., McMickle A., Fujihashi K., Kiyono H., McGhee J.R., Doherty P.C. Cytokine profiles of bronchoalveolar lavage cells from mice with influenza pneumonia: consequences of CD4+ and CD8+ T-cell depletion. Reg. Immunol. 5(3-4):1993;142-150.
46. Scott P. IL-12: Initiation cytokine for cell-mediated immunity. Science. 260:1993;496-497.
47. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T-cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168(5):1988;1675-1684.
48. Smith C.B. Influenza viruses. Gorbach S.L., Bartlett J.G., Blacklow N.R. Infectious Diseases. 1992;1740-1745 Saunders, Philadelphia, PA.
49. Straub M. The microscopical changes in the lungs of mice infected with influenza virus. J. Pathol. Bacteriol. 45:1937;75-78. Plates XVII-XX.
50. Sypek J.P., Chung C.L., Mayor S.E., Subramanyam J.M., Goldman S.J., Sieburth D.S., Wolf S.F., Schaub R.G. Resolution of cutaneous leishmaniasis: IL-12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177(6):1993;1797-1802.
51. Taylor S.F., Cottey R.J., Zander D.S., Bender B.S. Influenza infection of β2-microglobulin deficient (β2m-/-) mice reveals a loss of CD4+ T-cell functions with aging. J. Immunol. 159(7):1997;3453-3459.
52. H1 cells. Immunol. Today. 14(7):1993;335-338.
53. Trinchieri G., Scott P. The role of IL-12 in the immune response, disease and therapy. Immunol. Today. 15(10):1994;460-463.
54. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259(5102):1993;1745-1749.
55. Urban J.F. Jr., Fayer R., Chen S.J., Gause W.C., Gately M.K., Finkelman F.D. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum. J. Immunol. 156(1):1996;263-268.
56. Vacheron F., Rudent A., Perin S., Labarre C., Quero A.M., Guenounou M. Production of IL-1 and tumour necrosis factor activities in bronchoalveolar washings following infection of mice by influenza virus. J. Gen. Virol. 71(2):1990;477-479.
57. Van Campen H. Influenza A virus replication is inhibited by tumor necrosis factor-α in vitro. Arch. Virol. 136(3-4):1994;439-446.
58. Van Cleave V., Wolf S., Murray K., Wiencis A., Ketchum M., Bliss J., Haire T., Resmini C., Maylor R., Alderman E. Immunoglobulin isotype modulation after administration of IL-12. Adv. Exp. Med. Biol. 383:1995;43-52.
59. Wolf S.F., Temple P.A., Kobayashi M., Young D., Dicig M., Lowe L., Dzialo R., Fitz L., Ferenz C., Hewick R.M. et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T- and natural killer cells. J. Immunol. 146(9):1991;3074-3081.
60. Wyde P.R., Peavy D.L., Cate T.R. Morphological and cytochemical characterization of cells infiltrating mouse lungs after influenza infection. Infect. Immun. 21(1):1978;140-146.
61. Wynn T.A., Jankovic D., Hieny S., Cheever A.W., Sher A. IL-12 enhances vaccine-induced immunity to Schistosoma mansoni in mice and decreases T helper 2 cytokine expression, IgE production and tissue eosinophilia. J. Immunol. 154(9):1995;4701-4709.
62. Yetter R.A., Lehrer S., Ramphal R., Small P.A. Jr. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect. Immun. 29(2):1980;654-662.
63. Zhou P., Sieve M.C., Bennett J., Kwon Chung K.J., Tewari R.P., Gazzinelli R.T., Sher A., Seder R.A. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-γ J. Immunol. 155(2):1995;785-795.